Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Reexamination Certificate
1999-07-13
2009-10-20
Marschel, Ardin (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
Reexamination Certificate
active
07605149
ABSTRACT:
There is provided a method of modifying vasoactivity by regulating a soluble Aβ pro-inflammatory pathway. Also provided is a method of modifying inflammatory reactions in microglia and neurons by regulating a soluble Aβ pro-inflammatory pathway. A method of treating patients with vascular disease by modifying an intracellular soluble Aβ pro-inflammatory pathway is also provided. A pharmaceutical composition consisting essentially of an effective amount of a soluble Aβ pro-inflammatory pathway regulator in a pharmaceutically effective carrier is also provided.
REFERENCES:
patent: 3791932 (1974-02-01), Schuurs et al.
patent: 3839153 (1974-10-01), Schuurs et al.
patent: 3850578 (1974-11-01), McConnell
patent: 3850752 (1974-11-01), Schuurs et al.
patent: 3853987 (1974-12-01), Dreyer
patent: 3867517 (1975-02-01), Ling
patent: 3879262 (1975-04-01), Schuurs et al.
patent: 3901654 (1975-08-01), Gross
patent: 3935074 (1976-01-01), Rubenstein et al.
patent: 3984533 (1976-10-01), Uzgiris
patent: 3996345 (1976-12-01), Ullman et al.
patent: 4034074 (1977-07-01), Miles
patent: 4098876 (1978-07-01), Piasio et al.
patent: 4439196 (1984-03-01), Higuchi
patent: 4447224 (1984-05-01), DeCant, Jr. et al.
patent: 4447233 (1984-05-01), Mayfield
patent: 4475196 (1984-10-01), LaZor
patent: 4486194 (1984-12-01), Ferrara
patent: 4487603 (1984-12-01), Harris
patent: 4666828 (1987-05-01), Gusella
patent: 4683202 (1987-07-01), Mullis
patent: 4801531 (1989-01-01), Frossard
patent: 4879219 (1989-11-01), Wands et al.
patent: 4925678 (1990-05-01), Ranney
patent: 4959217 (1990-09-01), Sanders et al.
patent: 5011771 (1991-04-01), Bellet et al.
patent: 5167616 (1992-12-01), Haak et al.
patent: 5169383 (1992-12-01), Gyory et al.
patent: 5192659 (1993-03-01), Simons
patent: 5225182 (1993-07-01), Sharma
patent: 5272057 (1993-12-01), Smulson et al.
patent: 5281521 (1994-01-01), Trojanowski et al.
patent: 5700816 (1997-12-01), Isakson et al.
patent: 5932576 (1999-08-01), Anantanarayan et al.
patent: 6316464 (2001-11-01), Cheng et al.
patent: 6436983 (2002-08-01), Watanabe
patent: 9503297 (1995-02-01), None
patent: 99/25340 (1999-05-01), None
Jackson et al., The Journal of Pharmacology and Experimental Therapeutics, vol. 284, No. 2, 1998.
Abramovitz, M., E. Wong, M.E. Cox, C.D. Richardson, C. Li, and P.J. Vickers. 5-lipoxygenase-activating protein stimulates the utilization of arachidonic acid by 5-lipoxygenase.Eur. J. Biochem.215:105-11, 1993.
Arita, H., K. Hanasaki, T. Nakano, S. Oka, H. Teraoka, and K. Matsumoto. Novel proliferative effect of phospholipase A2 in Swiss 3T3 cells via specific binding site.J. Biol. Chem.266:19139-41, 1991.
Basso, D., C. Fabris, M.P. Panozzo, T. Meggiato, G. Del Favero, and R. Naccarato. Serum phospholipase A2 activity in chronic pancreatic diseases.Clin. Biochem.23:229-32, 1990.
Borsch-Haubold, A.G., S. Pasquet, and S.P. Watson. Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB 203580 and PD 98059. SB 203580 also inhibits thromboxane synthase.J. Biol. Chem.273:28766-72, 1998.
Clark, J.D., L.L. Lin, R.W. Kriz, C.S. Ramesha, L.A. Sultzman, A.Y. Lin, N. Milona, and J.L. Knopf.. A novel arachidonic acid-selective cytosolic PLA2 contains a Ca(2+)-dependent translocation domain with homology to PKC and GAP.Cell65:1043-1051, 1991.
Crawford, F., Z. Suo, C. Fang, and M. Mullan. Characteristics of the in Vitro Vasoactivity of beta-amyloid peptides.Exp. Neurol.150:159-168, 1998.
Dennis, E.A., S.G. Rhee, M.M. Billah, and Y.A. Hannun. Role of phospholipase in generating lipid second messengers in signal transduction.FASEB J.5:2068-77, 1991.
Dennis, E.A. The growing phospholipase A2 superfamily of signal transduction enzymes.Trends Biochem. Sci.22:1-2, 1997.
Duara, R., C. Grady, J. Haxby, M. Sundaram, N.R. Cutler, L. Heston, A. Moore, N. Schlageter, S. Larson, and S.I. Rapoport. Positron emission tomography in Alzheimer's disease.Neurology36:879-887, 1986.
Dudley, D.T., L. Pang, S.J. Decker, A.J. Bridges, and A.R. Saltiel.. A synthetic inhibitor of the mitogen-activated protein kinase cascade.Proc. Natl. Acad. Sci. U S A92:7686-9, 1995.
Ellis, R.J., J.M. Olichney, L.J. Thal, S.S. Mirra, J.C. Morris, D. Beekly, and A. Heyman. Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, Paart XV.Neurology46:1592-6, 1996.
Farooqui, A.A., S.I. Rapoport, and L.A. Horrocks. Membrane phospholipid alterations in Alzheimer's disease: deficiency of ethanolamine plasmalogens.Neurochem. Res.22:523-7, 1997.
Futaki, N., S. Takahashi, M. Yokoyama, I. Arai, S. Higuchi, and S. Otomo. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro.Prostaglandins47:55-9, 1994.
Glover, S., M.S. de Carvalho, T. Bayburt, M. Jonas, E. Chi, C.C. Leslie, and M.H. Gelb. Translocation of the 85-kDa phospholipase A2 from cytosol to the nuclear envelope in rat basophilic leukemia cells stimulated with calcium ionophore or IgE/antigen.J. Biol. Chem.270:15359-67, 1995.
Gravitt, K.R., N.E. Ward, and C.A. O'Brian.. Inhibition of protein kinase C by melittin: antagonism of binding interactions between melittin and the catalytic domain by active-site binding of MgATP.Biochem. Pharmacol.47:425-7, 1994.
Griffin, W.S.T., J.G. Sheng, G.W. Roberts, and R.E. Mrak. Interleukin-1 expression in different plaque types in Alzheimer's disease: significance in plaque evolution.J. Neuropathol. Exp. Neurol.54:276-281, 1995.
Han, S.K., B.I. Lee, and W. Cho. Bacterial expression and characterization of human pancreatic phospholipase A2.Biochim. Biophys. Acta.1346:185-92, 1997.
Hanasaki, K., Y. Yokota, J. Ishizaki, T. Itoh, and H. Arita. Resistance to endotoxic shock in phospholipase A2 receptor-deficient mice.J. Biol. Chem.272:32792-7, 1997.
Hernandez, M., S.L. Burillo, M.S. Crespo, and M.L. Nieto. Secretory phospholipase A2 activates the cascade of mitogen-activated protein kinases and cytosolic phospholipase A2 in the human astrocytoma cell line 1321N1.J. Biol. Chem.273:606-12, 1998.
Husain, S., and A.A. Abdel-Latif. Role of protein kinase C alpha in endothelin-1 stimulation of cytosolic phospholipase A2 and arachidonic acid release in cultured cat iris sphincter smooth muscle cells.Biochim. Biophys. Acta.1392-127-44, 1998.
Huwiler, A., G. Staudt, R.M. Kramer, and J. Pfeilschifter. Cross-talk between secretory phospholipase A2 and cytosolic phospholipase A2 in rat renal mesangial cells.Biochim. Biophys. Acta.1348:257-72, 1997.
Iadecola, C., F. Zhang, K. Niwa, C. Eckman, S.K. Turner, E. Fischer, S. Younkin, D.R. Borchelt, K.K. Hsiao, and G.A. Carlson. SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein.Nat. Neurosci.2:157-61, 1999.
Ishizaki, J., K. Hanasaki, K. Higashino, J. Kishino, N. Kikuchi, O. Ohara, and H. J. Arita. Molecular cloning of pancreatic group I phospholipase A2 receptor.Biol. Chem.269:5897-904, 1994.
Itagaki, S., P.L. McGeer, H. Akiyama, S. Zhu, and D. Selkoe. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease.J. Neuroimmunol.24:173-182, 1989.
Iversen, L.L., R.J. Mortishire-Smith, S.J. Pollack, and M.S. Shearman, The toxicity in vitro of beta-amyloid protein.Biochem. J.311:1-16, 1995.
Iwamoto, N., K. Kobayashi, and K. Kosaka. The formation of prostaglandins in the postmortem cerebral cortex of Alzheimer-type dementia patients.J. Neurol.236:80-4, 1989.
Jeandel, C., M.B. Nicolas, F. Dubois, F. Nabet-Belleville, F. Penin, and G. Cuny. Lipid peroxidation and free radical scavengers in Alzheimer's disease.Gerontology35:275-82, 1989.
Johnson, K.A., S.T. Mueller, T.M. Walshe, R.j. English, and B.L. Holman. Cerebral perfusion imaging in Alzheimer's disease. Use of a single photon emission computed tomography and iofetamine hydrochloride I 123.Arch. Neurol.44:165-168, 1987.
Joyce-Brady, M., J.B. Rubins, M.P. Panchenko, J. Bernardo, M.P. Steele, L. Kolm, E.R Simons, and B.F. Dickey. Mechanisms of mastoparan-stimulated surfactant secretion from isolated pulmonary alveolar type 2 cells.J. Biol. Chem.266:6859-65, 1991.
Kan
Mullan Michael J.
Paris Daniel
Town Terrence C.
Anderson James D
Marschel Ardin
University of South Florida
LandOfFree
Modulation of the phospholipase A2 pathway as a therapeutic does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulation of the phospholipase A2 pathway as a therapeutic, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulation of the phospholipase A2 pathway as a therapeutic will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4074780